doi:10.1177/0004563220980495engFabre, M.Ruiz-Martinez, S.Monserrat Cantera, M.E.Cortizo Garrido, A.Beunza Fabra, Z.Peran, M.Benito, R.Mateo, P.Paules, C.Oros, D.SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend?ART-2020-121660Background: An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an efficient screening tool during pregnancy. Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients. Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.2020http://zaguan.unizar.es/record/9746310.1177/0004563220980495http://zaguan.unizar.es/record/97463oai:zaguan.unizar.es:97463info:eu-repo/grantAgreement/ES/ISCIII/CM18-00202info:eu-repo/grantAgreement/ES/ISCIII/JR19-00006ANNALS OF CLINICAL BIOCHEMISTRY 58, 2 (2020), 149-152by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess